Laura Pierce (Fed)

RESEARCH INTERESTS

• Cell therapy and regenerative medicine
• Measurement assurance strategies
• Cell counting and cell viability measurements
• Metabolic assays
• Oncology applications
• High-throughput screening and automation
• Machine learning for cell morphology characteristics

ACTIVITIES

• Mentor, NIST MC Internship Program (2019 – present)
• Mentor, NIST SURF Student Program (2017)
• Abstract accepted and presented at Southeast Biomedical Engineering Conference, Washington, DC.  Paper entitled “The serum of sickle cell patients induces translocation and abnormal function of endothelial nitric oxide synthase.”

PATENT

• Combinations for the Treatment of B-cell Proliferative Disorders. Richard Rickles, Laura Pierce, Margaret S. Lee. Pub. No. 2009/0047243 A1. Pub. Date Feb. 19, 2009.

AWARDS

• Department of Commerce Gold Award 2022
• Best Student Presentation Award, Society for Physical Regulation in Biology and Medicine annual conference, 2002.  Presentation entitled “Oxysterol mediated endothelial dysfunction in sickle cell disease.”
• Student travel scholarship to attend Society for Physical Regulation in Biology and Medicine annual conference, 2002, San Diego, CA.
• GE Fellowship Award, Northeastern University, August 2000.  Awarded annually to one qualified student entering chemical engineering department.

SELECTED PUBLICATIONS

• A Screen of Approved Drugs and Molecular Probes Identifies Therapeutics with Anti- Ebola virus Activity. Lisa Johansen1, Lisa Evans DeWald2, Charles J. Shoemaker3, Benjamin G. Hoffstrom1, Calli M. Lear-Rooney2, Andrea Stossel2, Elizabeth Nelson3, Sue E. Delos3, Jill M. Grenier1, Laura T. Pierce1, Hassan Pajouhesh1, Joseph Lehár 1,4, Lisa E. Hensley2, Pamela J. Glass2, Judith M. White3, and Gene G. Olinger2,† Sci Transl Med. 2015 Jun 3;7(290):290ra89
• Adenosine A2A and Beta-2 Adrenergic Receptor Agonists: Novel Selective and Synergistic Multiple Myeloma Targets Discovered through Systematic Combination Screening.  Rickles RJ, Tam WF, Giordano TP, Pierce LT, Farwell M, McMillin DW, Necheva A, Crowe D, Chen M, Avery W, Kansra V, Nawrock ST, Carew JS, Giles F, Mitsiades CS, Borisy AA, Anderson KC, Lee MS. Mol Cancer Ther. 2012 Jul;11(7):1432-42.
• Adenosine A2A receptor agonists and PDE inhibitors: a synergistic multi-target mechanism discovered through systematic combination screening in B-cell malignancies. Richard J Rickles, Laura T Pierce, Thomas P Giordano, Winnie F Tam, Douglas W McMillin, Jake Delmore, Jacob P Laubach, Alexis A Borisy, Paul G Richardson, and Margaret S Lee. Blood. 2010 Jul 29; 116(4): 593-602.